


PHARMACEUTICAL 2019

IVERIC bio Inc. Rank 3 of 371





PHARMACEUTICAL 2019



IVERIC bio Inc. Rank 3 of 371

The relative strengths and weaknesses of IVERIC bio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IVERIC bio Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 841% points. The greatest weakness of IVERIC bio Inc. is the variable Revenues, reducing the Economic Capital Ratio by 151% points.

The company's Economic Capital Ratio, given in the ranking table, is 522%, being 853% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	133,287
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,206
Liabilities, Non-Current	0
Other Assets	3,543
Other Compr. Net Income	0
Other Expenses	-1,063
Other Liabilities	0
Other Net Income	127,373
Property and Equipment	335
Research and Development	41,737
Revenues	0
Selling, General and Administrative Expense	23,612

Output Variable	Value in 1000 USD
Assets	137,165
Liabilities	13,206
Expenses	64,286
Stockholders Equity	123,959
Net Income	63,087
Comprehensive Net Income	63,087
Economic Capital Ratio	522%